Jan 28 (Reuters) - Beta Bionics is targeting a valuation of up to $695 million in an upsized initial public offering, the insulin delivery device maker said on Tuesday.
The company will aim to raise up to $170 million through a sale of 10 million shares priced between $16 and $17 each. It was earlier targeting proceeds of $120 million.
Beta bucks the recent trend where major IPO candidates such as LNG exporter Venture Global VG.N and pork producer Smithfield Foods had to lower their valuation targets.
Analysts have said that the demand for new share sales remains strong but new entrants will need to aim for more realistic valuations.
Wellington Management, a Beta shareholder, has agreed to purchase $17 million worth of the company's shares in a concurrent private placement at the IPO price.
Beta's shares will start trading on the Nasdaq under the symbol "BBNX". BofA Securities, Piper Sandler, Leerink Partners, Stifel and Lake Street are the underwriters for the offering.
(Reporting by Niket Nishant in Bengaluru; Editing by Shinjini Ganguli)
((Niket.Nishant@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。